Zymogenetics, Inc.

Juno Therapeutics Gmbh

Other

Bristol-myers Squibb Compnay

Editas Medicine, Inc.

Cameron Brandt

Brian A Fox

Wenfeng Xu

Zeren Gao

Scott R Presnell

Donald C Foster

Cindy A Sprecher

Mark W Rixon

James D Kelly

Karen L Madden

Eugene C Yi

Alexandra Croft

Jacob J Kennedy

James William West

Janine M Bilsborough

Steven D Levin

Pallavur V Sivakumar

Stephen Jacob Goldfless

Brian J Belmont

Eric Chadwick

Frederick J Ramsdell

Haley Peper

James Sissons

David Jeffrey Huss

Dean Y Toy

Blythe D Sather

Yue Jiang

Christopher Heath Nye

Stephen Michael Burleigh

Gordon Grant Welstead

Timothy G Johnstone

Allen Ebens

Queenie Vong

Christopher Borges

David Koppstein

Hieu Nguyen

Sonia Timberlake

Eric M Chadwick

Edward D Howard

Provided are binding molecules, such as TCRs or antigen binding fragments thereof and antibodies and antigen-binding fragments thereof, such as those that recognize or bind human papilloma virus (HPV) 16, including HPV 16 E6 and HPV 16 E7. Also provided are engineered cells containing such binding molecules, compositions containing the binding molecules or engineered cells, and methods of treatment, such as administration of the binding molecules, engineered cells, or compositions.

HPV-specific binding molecules

Provided herein are binding molecules, such as those that recognize or bind a peptide epitope of a cancer antigen, such as expressed on a cancer cell, including cells infected with human papilloma virus (HPV) or that contain HPV DNA sequences and/or those that recognize or bind a peptide epitope of HPV 16 E6 or E7, in the context of a major histocompatibility complex (MHC) molecule. Among the provided binding molecules are T cell receptors (TCRs) or antibodies, including antigen-binding fragments thereof, that bind or recognize such peptide epitopes. The present disclosure further relates to engineered cells comprising such binding molecules, e.g., TCRs or antibodies (and chimeric antigen receptors containing the antibodies), and uses thereof in adoptive cell therapy.

T cell receptors and engineered cells expressing same

Disclosed is a newly identified B7 family member, zB7H6, which functions as a counter-receptor for the NK cell triggering receptor, NKp30. Methods and compositions for modulating NKp30-mediated NK cell activity based on the interaction of zB7H6 with NKp30, as well as related screening methods, are also disclosed. Further disclosed are anti-zB7H6 antibodies as well as antibody-drug conjugates comprising an anti-zB7H6 antibody conjugated to a therapeutic agent, including methods for using such antibodies and antibody-drug conjugates to exert therapeutic effects against zB7H6-expressing cells.

B7 family member zB7H6 and related compositions and methods

The present invention provides a newly identified B7 receptor, zB7R1 that functions as lymphocyte inhibitory receptor, which is a PD-1-like molecule and is expressed on T cells. The present invention also provides the discovery of zB7R1's ability to bind to CD155. Methods and compositions for modulating zB7R1-mediated negative signaling and interfering with the interaction of its counter-receptor for therapeutic, diagnostic and research purposes are also provided.

Method of treating CD155 expressing cancers

Screening method for inhibitors of binding of zBR7R1 to CD155

A soluble receptor to IL-20 having two polypeptide subunits, IL-20RA (formerly called ZcytoR7) and IL-20RB (formerly called DIRS1). The two subunits are preferably linked together. In one embodiment one subunit is fused to the constant region of the light chain of an immunoglobulin, and the other subunit is fused to the constant region of the heavy chain of the immunoglobulin. The light chain and the heavy chain are connected via a disulfide bond.

Methods of treating inflammatory disease using a soluble IL-20 receptor

Anti-zB7H6 antibody-drug conjugates

Soluble interleukin-20 receptor

Soluble Interleukin-20 receptor

Growing community of inventors

Seattle, WA, United States of America

Cameron Brandt